• Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451).
  

PubMed=22002331; DOI=10.3892/ijo.2011.1235
Rinner B., Froehlich E.V., Buerger K., Knausz H., Lohberger B., Scheipl S., Fischer C., Leithner A., Guelly C., Trajanoski S., Szuhai K., Liegl-Atzwanger B.
Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1.
Int. J. Oncol. 40:443-451(2012)

PubMed=27102572; DOI=10.1002/path.4729
Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H., Zuercher W.J., Turlais F., Ye H.-T., Leite A.P., Smith J.A., Leithner A., Moller P., Bruderlein S., Guppy N., Amary F., Tirabosco R., Strauss S.J., Pillay N., Flanagan A.M.
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
J. Pathol. 239:320-334(2016)

PubMed=28515451; DOI=10.1038/s41598-017-02174-5
Jager D., Barth T.F.E., Bruderlein S., Scheuerle A., Rinner B., von Witzleben A., Lechel A., Meyer P., Mayer-Steinacker R., von Baer A., Schultheiss M., Wirtz C.R., Moller P., Mellert K.
HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.
Sci. Rep. 7:2032-2032(2017)

PubMed=28835717; DOI=10.1038/s41598-017-10044-3
Bosotti R., Magnaghi P., Di Bella S., Cozzi L., Cusi C., Bozzi F., Beltrami N., Carapezza G., Ballinari D., Amboldi N., Lupi R., Somaschini A., Raddrizzani L., Salom B., Galvani A., Stacchiotti S., Tamborini E., Isacchi A.
Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.
Sci. Rep. 7:9226-9226(2017)